No Evidence for a Putative Involvement of Platelet-activating Factor in Systemic Lupus Erythematosus Without Active Nephritis

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2003 May 31

PMID 12775360

Authors

Yves Denizot

Eric Liozon

Laurence Guglielmi

Kim Ly

Pascale Soria

Veronique Loustaud

Elisabeth Vidal

Marie Odile Jauberteau

Affiliations

Soon will be listed here.

Abstract

Background: Platelet-activating factor (PAF) seems to be implicated in systemic lupus erythematosus (SLE) patients with associated renal diseases.

Aims: In this study, we ensured the role of PAF in SLE patients without renal complications.

Methods: Blood PAF and acetylhydrolase activity, plasma soluble phospholipase A(2), and the presence of antibodies against PAF were investigated in 17 SLE patients without active nephritis and in 17 healthy controls.

Results: Blood PAF levels were not different (p=0.45) between SLE patients (6.7+/-2.8 pg/ml) and healthy subjects (9.6+/-3.1 pg/ml). Plasma acetylhydrolase activity (the PAF-degrading enzyme) was significantly (p=0.03) elevated in SLE patients (57.8+/-6.4 nmol/min/ml) as compared with controls (37.9+/-2.6 nmol/min/ml). Plasma soluble phospholipase A(2) (the key enzyme for PAF formation) was not different (p=0.6) between SLE patients (59.1+/-5.1 U/ml) and controls (54.7+/-2.4 U/ml). Antibodies against PAF were detected only in 3/17 SLE patients. Flow cytometry analysis did not highlight PAF receptors on circulating leukocytes of SLE patients.

Conclusion: This clinical study highlights no evidence for a putative important role of PAF in SLE patients without active nephritis.

References

Vila L, Mayor A, Valentin A, Vila S . Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus. Lupus. 2000; 9(2):110-5. DOI: 10.1191/096120300678828073. View

Lopez-Novoa J . Potential role of platelet activating factor in acute renal failure. Kidney Int. 1999; 55(5):1672-82. DOI: 10.1046/j.1523-1755.1999.00450.x. View

Denizot Y, Aupetit C, Bridoux F, Alphonse J, Cogne M, Aldigier J . Deregulated platelet-activating factor levels and acetylhydrolase activity in patients with idiopathic IgA nephropathy. Nephrol Dial Transplant. 2000; 15(9):1344-7. DOI: 10.1093/ndt/15.9.1344. View

Bussolati B, Rollino C, Mariano F, Quarello F, Camussi G . IL-10 stimulates production of platelet-activating factor by monocytes of patients with active systemic lupus erythematosus (SLE). Clin Exp Immunol. 2000; 122(3):471-6. PMC: 1905813. DOI: 10.1046/j.1365-2249.2000.01392.x. View

Denizot Y, Desplat V, Drouet M, Bertin F, Melloni B . Is there a role of platelet-activating factor in human lung cancer?. Lung Cancer. 2001; 33(2-3):195-202. DOI: 10.1016/s0169-5002(01)00197-0. View

Tan E, Cohen A, Fries J, MASI A, McShane D, Rothfield N . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25(11):1271-7. DOI: 10.1002/art.1780251101. View

Tetta C, Bussolino F, Modena V, Montrucchio G, Segoloni G, Pescarmona G . Release of platelet-activating factor in systemic lupus erythematosus. Int Arch Allergy Appl Immunol. 1990; 91(3):244-56. DOI: 10.1159/000235124. View

Baldi E, Emancipator S, Hassan M, Dunn M . Platelet activating factor receptor blockade ameliorates murine systemic lupus erythematosus. Kidney Int. 1990; 38(6):1030-8. DOI: 10.1038/ki.1990.309. View

Morigi M, Macconi D, Riccardi E, Boccardo P, Zilio P, Bertani T . Platelet-activating factor receptor blocking reduces proteinuria and improves survival in lupus autoimmune mice. J Pharmacol Exp Ther. 1991; 258(2):601-6. View

10.

Ammit A, ONeill C . Comparison of a radioimmunoassay and bioassay for embryo-derived platelet-activating factor. Hum Reprod. 1991; 6(6):872-8. DOI: 10.1093/oxfordjournals.humrep.a137443. View

11.

Mazer B, SAWAMI H, Franklin R, Gelfand E . B-cell activation and regulation of immunoglobulin synthesis by platelet activating factor. Neth J Med. 1991; 39(3-4):244-53. View

12.

Bombardier C, Gladman D, Urowitz M, Caron D, Chang C . Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992; 35(6):630-40. DOI: 10.1002/art.1780350606. View

13.

Baldo B, Smal M, McCaskill A . A specific, sensitive and high-capacity immunoassay for PAF. Lipids. 1991; 26(12):1136-9. DOI: 10.1007/BF02536517. View

14.

Matsuzaki M, Ishiguro Y, Tetsumoto T, Tsukada Y, Kayahara H, Tadasa K . PAF acetylhydrolase activities in human systemic lupus erythematosus and lupus-prone mice. Clin Chim Acta. 1992; 210(1-2):139-44. DOI: 10.1016/0009-8981(92)90052-r. View

15.

McManus L, Woodard D, Deavers S, Pinckard R . PAF molecular heterogeneity: pathobiological implications. Lab Invest. 1993; 69(6):639-50. View

16.

Smith C, Shearer W . Activation of NF-kappa B and immunoglobulin expression in response to platelet-activating factor in a human B cell line. Cell Immunol. 1994; 155(2):292-303. DOI: 10.1006/cimm.1994.1123. View

17.

Barquinero J, Ordi-Ros J, Selva A, Vilardell M, Khamashta M . Antibodies against platelet-activating factor in patients with antiphospholipid antibodies. Lupus. 1994; 3(1):55-8. DOI: 10.1177/096120339400300111. View

18.

Shirasaki H, Adcock I, Kwon O, Nishikawa M, Mak J, Barnes P . Agonist-induced up-regulation of platelet-activating factor receptor messenger RNA in human monocytes. Eur J Pharmacol. 1994; 268(2):263-6. DOI: 10.1016/0922-4106(94)90197-x. View

19.

Leong K, Koh E, Feng P, Boey M . Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol. 1994; 21(7):1264-7. View

20.

Imaizumi T, Stafforini D, Yamada Y, McIntyre T, Prescott S, Zimmerman G . Platelet-activating factor: a mediator for clinicians. J Intern Med. 1995; 238(1):5-20. DOI: 10.1111/j.1365-2796.1995.tb00894.x. View